SCHEMBL5840709

SCHEMBL5840709

COC(=O)c1cc(Br)c([N+](=O)[O-])s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 1/20 0.39
USP10 Q14694 1/20 0.39
VCAM1 P19320 1/20 0.38
HPGD P15428 5/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPK1 P28482 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.37
ATM Q13315 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CSNK2A2 P19784 1/20 0.37
KDR P35968 1/20 0.37
CSNK2B P67870 1/20 0.37
CSNK2A1 P68400 1/20 0.37
COMT P21964 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6508901 0.83 DAO (0.38) PTPN2KDM4EALDH1A1MEN1KMT2A
SCHEMBL8363261 0.82 USP10 (0.42) USP10VCAM1HPGDKDM4EALDH1A1
SCHEMBL6513961 0.81 USP2 (0.54) HPGDKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL31330200 0.81 COMT (0.42) USP10VCAM1HPGDKDM4EALDH1A1
SCHEMBL6511511 0.80 POLB (0.54) HPGDKDM4EALDH1A1SMN1; SMN2MAPK1
SCHEMBL24578190 0.79 USP10 (0.43) USP10VCAM1HPGDKDM4EALDH1A1
SCHEMBL27631186 0.79 OPRD1 (0.40) USP10VCAM1HPGDKDM4EALDH1A1
SCHEMBL3880847 0.77 USP10 (0.47) USP10VCAM1HPGDKDM4EALDH1A1
SCHEMBL6511520 0.76 POLB (0.57) HPGDKDM4EALDH1A1SMN1; SMN2NPC1
SCHEMBL1529974 0.75 GSK3B (0.53) PTPN2HPGDKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4706757-A2 2-(((2,3-DIHYDROBENZO[B][1,4]DIOXAN-5-YL)PIPERIDIN-1-YL)METHYL)-1-((OXETAN-2-YL)METHYL)-1H-BENZO[D]IMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS GLP-1 MODULATORS FOR THE TREATMENT OF DIABETES Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2026-03-11 EP disclosed
EP-4209490-B1 2-(((2,3-DIHYDROBENZO[B][1,4]DIOXAN-5-YL)PIPERIDIN-1-YL)METHYL)-1-((OXETAN-2-YL)METHYL)-1H-BENZO[D]IMIDAZOLE-6-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS GLP-1 MODULATORS FOR THE TREATMENT OF DIABETES JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) 2026-01-28 EP disclosed
US-12473279-B2 Fused imidazole derivative, preparation method therefor, and medical use thereof JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2025-11-18 US disclosed
US-12459937-B2 Fused imidazole derivative, preparation method therefor, and medical use thereof JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2025-11-04 US disclosed
US-20250282773-A1 FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2025-09-11 US disclosed
US-20250243195-A1 FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2025-07-31 US disclosed
US-20250206757-A1 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES GASHERBRUM BIO, INC. 2025-06-26 US disclosed
CN-119954797-A Condensed imidazole derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2025-05-09 CN disclosed
CN-119930605-A Condensed imidazole derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2025-05-06 CN disclosed
CN-119930603-A Condensed imidazole derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2025-05-06 CN disclosed
CN-100412073-C Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions DIMENSIONAL PHARM INC (US) 2008-08-20 CN disclosed
US-7138530-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-11-21 US disclosed
US-7109354-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-09-19 US disclosed
EP-1549632-A4 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS DIMENSIONAL PHARM INC (US) 2005-11-09 EP disclosed
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions SUBASINGHE NALIN 2005-10-20 US disclosed
WO-2005082899-A1 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES LIMITED (IN) 2005-09-09 WO disclosed
CN-1665800-A Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions DIMENSIONAL PHARM INC (US) 2005-09-07 CN disclosed
EP-1549632-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2005-07-06 EP disclosed
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-01-15 US disclosed
WO-2003099805-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R PTPN2 1065/4885USP10 3376/4885VCAM1 3273/4885
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R PTPN2 1087/4885USP10 3962/4885VCAM1 3003/4885
US-12459937-B2 Fused imidazole derivative, preparation method therefor, and medical use thereof GLP1R, GIPR, VIP PTPN2 3427/4885USP10 3926/4885VCAM1 849/4885
US-20250206757-A1 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES GLP1R, IAPP, GPR119 PTPN2 866/4885USP10 3726/4885VCAM1 745/4885
US-12473279-B2 Fused imidazole derivative, preparation method therefor, and medical use thereof GLP1R, GIPR, VIP PTPN2 3427/4885USP10 3926/4885VCAM1 849/4885
US-20250282773-A1 FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF GLP1R, GIPR, VIP PTPN2 3427/4885USP10 3926/4885VCAM1 849/4885
US-20250243195-A1 FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF GLP1R, GIPR, VIP PTPN2 3427/4885USP10 3926/4885VCAM1 849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.